A study from Modelska et al. [38] has revealed that high levels of eIF4A1, eIF4B and eIF4E are all linked to unfavourable clinical outcomes for ER− BC patients, whereas the tumour suppressor programmed cell death 4 (PDCD4), which binds to and inhibits eIF4A [157], is positively correlated with favourable outcomes in ER+ BC patients. Here, EIF4B is linked to breast cancer.